Pexidartinib and Patients with Hepatic Impairment

In this article, we will discuss Pexidartinib and Patients with Hepatic Impairment. So, let’s get started.

Pexidartinib and Patients with Hepatic Impairment

The pharmacokinetics of pexidartinib has not been adequately characterized in patients with moderate hepatic impairment (total bilirubin > 1.5 to 3 × ULN and any AST) or studied in patients with severe hepatic impairment (total bilirubin > 3 to 10 × ULN and any AST).

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.